Therapy Detail

Therapy Name BAY1895344
Synonym
Therapy Description

BAY1895344 is a selective Atr inhibitor that inhibits proliferation of a variety of tumor cells (Proceedings of the AACR, Vol 58, Apr 2017, Abstract 983).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BAY1895344 ATR Inhibitor 10 BAY1895344 is a selective Atr inhibitor that inhibits proliferation of a variety of tumor cells (Proceedings of the AACR, Vol 58, Apr 2017, Abstract 983).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM mutant Advanced Solid Tumor predicted - sensitive BAY1895344 Phase I Actionable In a Phase I trial, BAY 1895344 treatment resulted in an objective response rate of 30.7% (4/13) in patients with advanced solid tumors, all responders harbored ATM protein expression loss and/or ATM mutations (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965). detail...
ATM negative Advanced Solid Tumor predicted - sensitive BAY1895344 Phase I Actionable In a Phase I trial, BAY 1895344 treatment resulted in an objective response rate of 30.7% (4/13) in patients with advanced solid tumors, all responders harbored ATM protein expression loss and/or ATM mutations (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965). detail...
BRCA1 mutant ovarian cancer predicted - sensitive BAY1895344 Case Reports/Case Series Actionable In a Phase I trial, BAY 1895344 treatment resulted in stable disease lasting over 10 months in a patient with BRCA1-mutant, Lynparza (olaparib)-resistant ovarian cancer (J Clin Oncol 37, 2019 (suppl; abstr 3007); NCT03188965). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting